Mirae Asset Global ETFs Holdings
KYTX icon

Mirae Asset Global ETFs Holdings’s Kyverna Therapeutics KYTX Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,912
Closed -$28.8K – 3278
2025
Q1 		$28.8K Buy
14,912
+624
+4% +$1.84K ﹤0.01% 2934
2024
Q4 		$53.4K Buy
14,288
+4,990
+54% +$23.9K ﹤0.01% 2888
2024
Q3 		$45.5K Buy
+9,298
New +$71.7K ﹤0.01% 2930

Other funds holding KYTX

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MPM
MBB Public Markets Chicago, Illinois $839M AUM 20.48% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's KYTX Position: Q2 2025 in Review

Mirae Asset Global ETFs Holdings sold out of Kyverna Therapeutics (KYTX) in Q2 2025, closing a stake of 14,912 shares — an estimated $28.8K sold.

Mirae Asset Global ETFs Holdings first reported a position in KYTX in Q3 2024 and held it in 3 quarters. The position peaked at $53.4K in Q4 2024. 79 funds tracked by Wall St. Rank hold KYTX as of Q2 2025.

  • Mirae Asset Global ETFs Holdings reported no remaining Kyverna Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Mirae Asset Global ETFs Holdings sold 14,912 Kyverna Therapeutics shares in Q2 2025, an estimated $28.8K.
  • Mirae Asset Global ETFs Holdings first reported a position in Kyverna Therapeutics in Q3 2024 and held it in 3 quarters.
  • Mirae Asset Global ETFs Holdings's Kyverna Therapeutics position peaked at $53.4K in Q4 2024.
  • 79 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2025.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2025, filed 14 Aug 2025.